-
- 1800 2010
- EN
News
Array
(
[0] => stdClass Object
(
[id] => 1446
[id_crawler] =>
[category_product] => NULL
[thumbnail] => huyen.8.2021/02-2022/4.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2026-05-21
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2026-05-21 14:42:43
[updated_time] => 2026-05-22 08:51:19
[files] =>
[salary] =>
[time] =>
[created_by] => 1
[is_table_content] => 0
[language_code] => en
[slug] => eurofins-gentis-xuat-sac-dat-2-giai-thuong-tieu-bieu-tai-the-best-of-vietnam-2026
[title] => Eurofins GENTIS excellently wins two prestigious awards at The Best of Vietnam 2026
[description] => At The Best of Vietnam 2026 Awards Ceremony held on May 16, Eurofins Genetic Testing Service Joint Stock Company (Eurofins GENTIS) was honored to receive two prestigious awards: Top 3 Best Brand in Vietnam 2026 in the field of Genetic Analysis and Best Product/Service in Vietnam 2026.
[content] => Affirming Brand Leadership in Genetic Analysis
The Best of Vietnam 2026 is an annual program established to honor enterprises with outstanding achievements in product and service quality, innovation capability, and meaningful contributions to the community.
This year, the program was jointly organized and evaluated by Intellectual Property & Creativity Magazine and the Joint Scientific Council, in collaboration with specialized institutions. Enterprises were assessed based on the official criteria set by the organizing committee to identify the most exemplary organizations.
Standing out among hundreds of competitors, Eurofins GENTIS has reaffirmed its pioneering position in the field of genetic testing and analysis by simultaneously receiving two prestigious awards: “Top 3 Best Brand in Vietnam 2026 in Genetic Analysis” and “Best Product/Service in Vietnam 2026.”
Eurofins GENTIS receives two prestigious awards: “Top 3 Best Brand in Vietnam 2026 in Genetic Analysis” and “Best Product/Service in Vietnam 2026”
With more than 15 years of establishment and development, Eurofins GENTIS has continuously invested in advanced technologies, enhanced professional expertise, and expanded its service ecosystem to meet the increasingly high demands of customers and healthcare facilities nationwide.
Eurofins GENTIS currently operates two modern laboratories in Hanoi and Ho Chi Minh City, along with a network of more than 50 sample collection points across Vietnam. The company has made comprehensive investments in advanced technologies such as Next-Generation Sequencing (NGS), Real-time PCR, Sanger sequencing, and Flow Cytometry, with a testing capacity of hundreds of thousands of samples annually.
All systems and analytical processes at Eurofins GENTIS laboratories are strictly controlled and meet rigorous international standards, including CAP certification, ISO 15189:2022, ISO 9001:2015, and ISO/IEC 27001:2022.
Certificate of Merit and Trophy of Eurofins GENTIS at The Best of Vietnam 2026
Eurofins GENTIS currently provides a wide range of advanced genetic testing services such as NIPT, PGT, WES, WGS, Genratest, paternity testing, and other modern assisted reproductive solutions. These services are delivered in accordance with international standards, aiming toward personalized healthcare and improved population health quality.
In addition, the company’s team of experts and laboratory technicians not only possess high professional qualifications but are also regularly trained and updated through collaborations with international partners as well as reputable medical universities in Vietnam and abroad.
Continuous Innovation for Community Health
Beyond investing in technology and enhancing professional expertise, Eurofins GENTIS consistently places customers at the center of all activities. The company focuses on optimizing service experience, improving consultation quality, and ensuring accuracy, safety, and confidentiality in every test result, thereby becoming a trusted reference for millions of customers nationwide.
Currently, Eurofins GENTIS is a professional partner of hundreds of hospitals, clinics, and assisted reproductive centers across the country. Through this extensive cooperation network, the company helps bring advanced genetic testing solutions closer to the public, effectively supporting screening, diagnosis, and treatment.
In addition to its professional activities, Eurofins GENTIS actively participates in community programs, scientific conferences, professional seminars, and continuous medical education activities. The company regularly collaborates with experts, physicians, and healthcare institutions to update the latest advances in genetics while promoting proactive health awareness within the community.
Mr. Hoang Dinh Khiem – Business Director of Eurofins GENTIS – represents the company in receiving the award at The Best of Vietnam 2026
Speaking at the ceremony, Mr. Hoang Dinh Khiem, Business Director of the company, shared: “Being honored in these two important categories is a great pride for the entire Eurofins GENTIS team. At the same time, it serves as a strong motivation for us to continue innovating, investing in technology, and improving service quality, bringing advanced genetic testing solutions that contribute to the healthcare and protection of the Vietnamese community.”
The recognition at The Best of Vietnam 2026 is not only an important milestone in Eurofins GENTIS’s development journey but also affirms the company’s reputation and capability in the field of genetic analysis in Vietnam.
In the coming time, Eurofins GENTIS will continue to accelerate technology investment, expand its testing ecosystem, and strengthen cooperation with healthcare institutions both domestically and internationally. With a sustainable development orientation, the company aims to become a leading organization in the field of genetics, delivering precise and modern medical solutions in pursuit of its mission: “Enhance the physical and intellectual capacity of Vietnamese people.”
[content_more] =>
[meta_title] => Eurofins GENTIS excellently wins two prestigious awards at The Best of Vietnam 2026
[meta_description] => At The Best of Vietnam 2026 Awards Ceremony held on May 16, Eurofins Genetic Testing Service Joint Stock Company (Eurofins GENTIS) was honored to receive two prestigious awards: Top 3 Best Brand in Vietnam 2026 in the field of Genetic Analysis and Best Pr
[meta_keyword] => gentis
[thumbnail_alt] =>
[post_id] => 1446
[category_id] => 4
)
[1] => stdClass Object
(
[id] => 1437
[id_crawler] =>
[category_product] => NULL
[thumbnail] => 3597520043414536654.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 0
[displayed_time] => 2026-05-18
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2026-05-18 10:04:24
[updated_time] => 2026-05-26 10:08:12
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => https://gentis.com.vn/tin-tuc-c4/eurofins-gentis-cap-nhat-cac-goi-xet-nghiem-sang-loc-so-sinh-d1437
[title] => Eurofins GENTIS Updates Newborn Screening Packages
[description] => Newborn screening is one of the crucial steps in healthcare that helps detect congenital disorders early in a child's life. Early detection not only allows for early intervention but also helps minimize the risk of complications and limit the impact on physical and intellectual development in the future.
[content] => To optimize practical application and better meet the needs of community screening, Eurofins GENTIS officially updates its newborn screening packages with more flexible and comprehensive options.
List of Newborn Screening Packages at Eurofins GENTIS
Currently, Eurofins GENTIS offers newborn screening packages including:
1. 5-Disease Newborn Screening
This is a basic screening package that helps detect early 5 common congenital diseases that can seriously affect a child's development if not treated promptly.
Diseases in the screening group: G6PD deficiency, Congenital hypothyroidism (TSH), Congenital adrenal hyperplasia (CAH), Galactosemia (GAL), Phenylketonuria (PKU). Early detection allows doctors to provide appropriate intervention from the early postpartum period.
2. Hemoglobin Screening
Hemoglobin testing helps detect abnormalities related to hemoglobin, especially genetic blood disorders such as:
- Thalassemia
- Sickle cell anemia
- Other abnormal hemoglobin variants
These are diseases with a relatively high carrier rate in many Asian countries, including Vietnam. Early screening plays a crucial role in monitoring health and managing long-term treatment for children.
3. Newborn Screening for 6 Diseases (5 Diseases + Hemoglobin)
This package combines:
- 5 basic disease screening package
- Hemoglobin test
This combination expands the scope of detection for congenital and inherited hematological diseases, providing a more comprehensive screening solution for newborns.
4. Screening for 77 Metabolic Disorders
Metabolic disorders (MDs) are a group of rare genetic diseases that can seriously affect the brain, liver, heart, or many other organs if not detected early.
The 77 MD screening test package is designed to detect many congenital metabolic disorders early through modern technology. Some diseases in this group may not show symptoms immediately after birth, but they progress rapidly and leave severe consequences if not treated promptly.
Early screening helps:
- Proactively monitor children's health
- Develop appropriate nutrition plans
- Reduce the risk of serious complications
- Improve children's quality of life
5. Screening for 82 diseases (5 diseases + 77 metabolic disorders)
This is an expanded test package, combining:
- Screening for 5 basic diseases
- Screening for 77 metabolic disorders
This test package is suitable for in-depth screening needs, helping to improve the ability to detect many important groups of congenital diseases early in the neonatal period.
6. Screening for 83 Diseases (5 Diseases + Hemoglobin + 77 Metabolic Disorders)
This is currently the most comprehensive screening package at Eurofins GENTIS, including:
- Screening for 5 basic diseases
- Hemoglobin test
- Screening for 77 metabolic disorders
This test package maximizes the scope of screening for congenital diseases, especially suitable for:
- Families wishing to perform comprehensive screening for their children
- Children with genetic risk factors
- Cases requiring in-depth health monitoring from early life
Why is newborn screening increasingly important?
According to many medical studies, there are many congenital diseases that do not show clear symptoms in the first few days after birth. Children may still develop normally in the early stages, however, the disease will silently progress and cause serious damage to the nervous system, cardiovascular system, liver, or intellectual development.
Newborn screening helps:
- Detect diseases before symptoms appear
- Increase treatment effectiveness
- Reduce the risk of serious complications
- Reduce the burden of care for families
- Improve the long-term quality of life for children
In particular, many diseases, if detected early, can be prevented from having serious consequences with simple nutritional interventions or treatments.
Eurofins GENTIS - Partnering with newborn health
This update to the testing packages demonstrates Eurofins GENTIS's efforts to improve the practical application and meet the increasingly diverse needs of the community in the field of newborn screening.
With a modern testing system and a strict quality control process, Eurofins GENTIS aims to support the early detection of congenital diseases, thereby giving children the opportunity to develop healthily from the very first days of life.
Parents should consult with their doctor to choose a testing package that suits their family's needs and circumstances. For detailed information about newborn screening packages, please contact Eurofins GENTIS.
[content_more] => [meta_title] => Eurofins GENTIS Updates Newborn Screening Packages [meta_description] => Newborn screening is one of the crucial steps in healthcare that helps detect congenital disorders early in a child's life. Early detection not only allows for early intervention but also helps minimize the risk of complications and limit the impact on ph [meta_keyword] => gentis [thumbnail_alt] => [post_id] => 1437 [category_id] => 4 ) [2] => stdClass Object ( [id] => 1435 [id_crawler] => [category_product] => NULL [thumbnail] => 687089645_1381819090649945_1976010304021238837_n.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2026-05-12 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-05-12 08:55:24 [updated_time] => 2026-05-21 15:11:54 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => https://gentis.com.vn/tin-tuc-c4/lop-hoc-tien-san-ve-chuyen-da-va-cac-phuong-phap-giup-san-phu-giam-dau-khi-sinh-d1435 [title] => Prenatal class on labor and pain relief methods during childbirth [description] => Pregnancy and childbirth are among the most sacred journeys in a woman’s life. However, alongside the happiness of preparing to welcome a little angel, many expectant mothers still feel anxious about labor, childbirth pain, and the physical changes that occur during delivery. Therefore, being well-equipped with prenatal knowledge plays an extremely important role in helping mothers feel more confident mentally and physically on the day of childbirth. [content] =>To accompany expectant mothers on their motherhood journey, a prenatal class titled “Labor and Pain Relief Methods During Childbirth” was held on May 8, 2026, at Andrology and Fertility Hospital of Hanoi, presented by Dr Hoang Tuan Linh. The class provided valuable and practical knowledge to help pregnant women better understand the labor process as well as safe pain relief methods during childbirth.
Labor - A Special Journey Before Meeting Your Baby
Labor marks the moment when a baby is ready to be born. During this stage, the mother’s body experiences uterine contractions that help the cervix dilate, allowing the baby to move through the birth canal. For many women, this is both an exciting and emotional period because labor pain often lasts for hours and gradually intensifies.
During the prenatal class, Dr Hoang Tuan Linh helped expectant mothers better understand:
- Important signs of labor and when to go to the hospital
- Physical changes during labor
- Pain relief methods during childbirth
- Breathing and relaxation techniques
- How to cooperate effectively with medical staff
- Important notes to help mothers prepare mentally before delivery
When equipped with the right knowledge and proper mental preparation, mothers can feel more confident throughout the childbirth journey and welcome their babies with positivity and happiness.
Prenatal Classes - Meaningful Preparation for Expectant Mothers
Prenatal classes are becoming increasingly popular and valuable for pregnant women. In addition to providing essential medical knowledge, these classes also offer opportunities for mothers to connect, share experiences, and ease anxiety before delivery.
The session on “Labor and Pain Relief Methods During Childbirth” attracted significant interest from participating mothers. Practical information combined with dedicated guidance from medical professionals helped attendees better understand the childbirth process and feel more confident entering labor.
Eurofins GENTIS was honored to collaborate with Andrology and Fertility Hospital of Hanoi in organizing meaningful prenatal classes for expectant mothers. This initiative not only provides valuable knowledge but also reflects the commitment to supporting families throughout the journey of welcoming their little angels into the world.
It is hoped that through these practical programs, expectant mothers will gain more useful knowledge, stronger mental preparation, and better health readiness to experience childbirth safely, gently, and with complete happiness.
[content_more] => [meta_title] => Prenatal class on labor and pain relief methods during childbirth [meta_description] => Pregnancy and childbirth are among the most sacred journeys in a woman’s life. However, alongside the happiness of preparing to welcome a little angel, many expectant mothers still feel anxious about labor, childbirth pain, and the physical changes that o [meta_keyword] => gentis [thumbnail_alt] => [post_id] => 1435 [category_id] => 4 ) [3] => stdClass Object ( [id] => 1434 [id_crawler] => [category_product] => NULL [thumbnail] => eurofins-gentis.png [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2026-05-08 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-05-08 13:45:03 [updated_time] => 2026-05-21 09:56:12 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => https://gentis.com.vn/tin-tuc-c4/thong-bao-eurofins-gentis-bi-gia-mao-yeu-cau-khach-hang-chuyen-tien-phi-van-chuyen-ket-qua-xet-nghiem-sang-loc-so-sinh-som-d1434 [title] => Notice Regarding Fraudulent Impersonation of Eurofins GENTIS Requesting Customers to Transfer Delivery Fees for Newborn Screening Test Results [description] => SECOND UPDATED NOTICE Regarding the impersonation of Eurofins GENTIS employees requesting customers to transfer shipping fees for newborn screening test results [content] =>Dear Valued Customers and Partners,
Recently, Eurofins GENTIS has received reports from several customers regarding suspicious phone calls from individuals falsely claiming to be company employees and requesting payment for the delivery of newborn screening test results to customers’ homes. Notably, the number of these fraudulent calls has been increasing.
In response to this situation, Eurofins GENTIS would like to clearly affirm that the company never calls customers to request money transfers via phone or personal bank accounts for any fees related to the delivery of test results. All service fees (if applicable) are publicly and transparently communicated at the time of registration and are processed strictly according to the official procedures of Eurofins GENTIS. In addition, we do not sell, disclose, or leak customers’ personal information in any form.
Currently, Eurofins GENTIS only uses the following official phone numbers to contact customers and provide newborn screening test result consultations:
- Hotline: 1800 2010
- Customer Service: 0388 002 010
- Result Consultation Numbers: 0962 400 240, 0906 269 799, and 0902 205 929
Any calls from other phone numbers requesting money transfers or personal information are not from Eurofins GENTIS.
In the context of rapid digital technology development, personal information may be collected from various sources and exploited for fraudulent activities, harassment, or even actions that seriously affect customers’ rights and property. Therefore, Eurofins GENTIS respectfully asks all customers and partners to remain vigilant, avoid sharing personal information, OTP codes, or bank account details, and never transfer money without properly verifying the information first.
If you receive suspicious calls or unusual information related to newborn screening test results, please contact Eurofins GENTIS directly through the following official channels for verification and timely support:
- Hotline: 1800 2010
- Customer Service: 0388 002 010
- Result Consultation Numbers: 0962 400 240, 0906 269 799, 0902 205 929
Eurofins GENTIS sincerely appreciates the trust and support of our valued customers and partners over the years. We also encourage everyone to share this information with family members and the community to help prevent unfortunate risks and fraudulent activities.
For further information, please contact:
EUROFINS GENTIS Hanoi
3rd Floor, V+ Commercial Center, 505 Minh Khai Street, Vinh Tuy Ward, Hanoi, Vietnam
EUROFINS GENTIS Ho Chi Minh City
8/24 Nguyen Dinh Khoi Street, Tan Son Nhat Ward, Ho Chi Minh City, Vietnam
- Hotline: 1800 2010 / 0388 002 010
- Email: CVN007_dichvu@eurofinsasia.com
Sincerely,
Eurofins GENTIS
The PGT process in assisted reproduction
According to Dr. Nguyen Van Thong, MD, Specialist Level I, Head of the Department of Medical Genetics at Hung Vuong Hospital, the current PGT process follows a structured pathway consisting of three main stages.
Stage 1: Pre-Test Counseling
In this stage, couples receive detailed consultations with fertility specialists and embryologists regarding the IVF process, the timing of embryo biopsy, and related technical considerations.
In particular, genetic counseling is an essential step. It helps assess the genetic risks associated with embryos and future pregnancies, while also identifying possible genetic causes in couples with a history of miscarriage, stillbirth, or children born with inherited diseases.
Once the genetic risks and the specific abnormalities to be tested are identified, the genetic specialist will explain the possible distribution of embryo outcomes. For example, among the embryos created, some may carry abnormalities, some may carry the same mutation as one parent but still develop normally, while others may be completely normal and free of mutations.
At this stage, couples and doctors work together to establish the final treatment goal. Some families simply hope to have a child, while others wish to select embryos free from any genetic abnormalities to reduce the burden of inherited diseases for future generations. This mutual understanding forms the foundation for the next steps.
Stage 2: Performing the PGT Test
After counseling is completed and consent forms are signed, the patient proceeds with the IVF cycle.
Embryos are cultured in the IVF laboratory until Day 3 or Day 5, with Day 5 blastocysts generally considered the optimal stage for biopsy. At this point, embryologists extract approximately 5 - 10 cells from the trophectoderm layer of the embryo. These cells are then placed into a specialized microtube and transferred to the genetics laboratory.
At the genetics lab, the testing process consists of two key steps:
- DNA Amplification:
DNA from the biopsied cells is amplified from just a few cells into millions of copies to provide sufficient material for analysis. - Genetic Analysis:
Advanced genetic technologies are then applied to determine whether the embryo carries chromosomal abnormalities, subchromosomal abnormalities, or single-gene mutations, depending on the original testing indication.
Stage 3: Post-Test Counseling
Once the PGT results are available, the couple meets again with the fertility doctor, genetic specialist, and embryologist.
At this point:
- The embryologist evaluates embryo morphology and development quality
- The genetic specialist analyzes the genetic quality of each embryo, identifying which embryos are suitable for transfer, which may not be appropriate, and which should be frozen for future consideration
Based on the genetic results, embryo morphology, and the family’s preferences, the medical team and the couple jointly develop an embryo transfer strategy. This includes determining:
- Which embryo should be prioritized for transfer first
- Which embryos may be transferred later
- Which embryos should not be used
This stage helps optimize the chances of achieving a healthy pregnancy while also ensuring patients have the right to make informed decisions and feel psychologically reassured throughout the process.
Eurofins GENTIS PGT Testing Achieves CAP Accreditation
In June 2025, Eurofins GENTIS officially achieved CAP accreditation for both NIPT and PGT testing, reaffirming its commitment to international quality standards.
CAP (College of American Pathologists) is one of the world’s leading laboratory accreditation organizations. CAP accreditation is considered the “gold standard” in laboratory quality assurance, with rigorous evaluation systems covering procedures, accuracy, quality control, and professional competency.
Achieving CAP accreditation demonstrates that Eurofins GENTIS PGT testing offers:
- High Accuracy:
Results validated according to strict international standards - Safety and Reliability:
Consistent operational procedures that minimize errors - Globally Standardized Laboratory Capability:
Full compliance with international requirements for equipment, personnel, and quality management systems - Commitment to Future Generations’ Health:
Especially in prenatal screening (NIPT) and assisted reproduction (PGT)
This achievement is not only a major milestone but also a strong commitment from Eurofins GENTIS to providing accurate, safe, and internationally standardized genetic testing solutions for customers.
[content_more] => [meta_title] => The PGT Testing Process in IVF [meta_description] => PGT (Preimplantation Genetic Testing) is a genetic analysis performed before embryo transfer to help select the best embryos - those without abnormalities in chromosome number or structure, or without disease-causing genetic mutations - for embryo transfe [meta_keyword] => gentis ,Pgt [thumbnail_alt] => PGT (Preimplantation Genetic Testing) is a genetic analysis performed before embryo transfer to help select the best embryos - those without abnormalities in chromosome number or structure, or without disease-causing genetic mutations - for embryo transfe [post_id] => 1433 [category_id] => 4 ) [5] => stdClass Object ( [id] => 1432 [id_crawler] => [category_product] => NULL [thumbnail] => 715c5e239a2b1b75423a.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2026-05-06 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-05-06 15:32:47 [updated_time] => 2026-05-21 09:46:33 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => https://gentis.com.vn/tin-tuc-c4/eurofins-gentis-cung-cap-danh-muc-xet-nghiem-pgt-toan-dien-d1432 [title] => Eurofins GENTIS provides a comprehensive PGT testing portfolio [description] => Preimplantation Genetic Testing (PGT) is becoming an essential tool for improving IVF success rates and reducing the risk of genetic abnormalities. Eurofins GENTIS offers a comprehensive portfolio of PGT tests, utilizing advanced technologies to support the selection of healthy embryos and optimize the journey to parenthood. [content] =>PGT-A/SR - Screening for Aneuploidy and Structural Chromosomal Abnormalities
PGT-A/SR is one of the most commonly used tests for detecting abnormalities in chromosome number and structure in embryos.
Detection Scope:
- Aneuploidy across all 24 chromosomes
- Structural chromosomal abnormalities such as large deletions or duplications greater than 5 Mb
Sample Type:
- Embryo biopsy on Day 3–5
Turnaround Time:
- 3 to 5 days
This test is particularly suitable for older couples, those with a history of recurrent miscarriage, or repeated IVF failures.
PGT FAST - Rapid Results Within 15 Hours
PGT FAST is an optimal solution for cases requiring rapid results to support fresh embryo transfer procedures.
Key Features:
- DNA analysis for detecting aneuploidy and structural abnormalities across all 24 chromosomes
- Detection of deletions and duplications larger than 5 Mb
Sample Type:
- Embryo biopsy on Day 3–5
Turnaround Time:
- Approximately 15 hours
With its exceptional speed, PGT FAST helps shorten waiting times and optimize the IVF treatment process.
PGT-M +100 Rare Diseases - Detection of Single-Gene Mutations
PGT-M is a specialized solution for families at risk of inherited single-gene disorders.
Detection Capabilities:
- Common inherited disorders such as Thalassemia, Spinal Muscular Atrophy (SMA), and Hemophilia
- Rare syndromes including Rett syndrome, Duchenne muscular dystrophy, and more than 100 other genetic diseases
Sample Type:
- Blood samples from both parents (2–3 ml whole blood collected in EDTA tubes)
- Embryo biopsy on Day 3–5
This test helps reduce the risk of children being born with inherited single-gene disorders, contributing to improved long-term quality of life.
PGT NEXT - Expanded Detection Capabilities
PGT NEXT is an advanced version that complements PGT-A/SR by detecting polyploid embryos and identifying embryos with normal diploid chromosome sets, even among abnormally fertilized embryos (e.g., 0PN, 1PN, or 2.1/3PN).
Detection Scope:
- Aneuploidy across all 24 chromosomes
- Structural chromosomal abnormalities (duplications/deletions > 5 Mb)
- Detection of special numerical abnormalities such as polyploidy and haploidy
Sample Type:
- Embryo biopsy on Day 5
This test is suitable for cases requiring deeper evaluation of embryo genetic quality.
PGT Upgrade - Detection of Balanced Translocations
PGT Upgrade is specifically designed for couples carrying balanced chromosomal translocations who wish to avoid passing them on to future generations.
Detection Scope:
- Aneuploidy across all 24 chromosomes
- Structural chromosomal abnormalities (duplications/deletions > 5 Mb)
- Detection of embryos carrying balanced translocations inherited from parents
Sample Type:
- Blood samples from both parents (2–3 ml whole blood) and balanced translocation test results
- Day 5 embryo biopsy samples
This test plays a critical role in selecting embryos free from inherited genetic abnormalities, increasing the chances of having a healthy child.
PGT Max 1 - Enhanced Detection of Common Microdeletions
PGT Max 1 is an optimized solution combining aneuploidy screening with the detection of significant microdeletion syndromes.
Detection Scope:
- Aneuploidy across all 24 chromosomes
- Structural chromosomal abnormalities (duplications/deletions > 5 Mb)
- Detection of two common microdeletion syndromes:
- 22q11.2 deletion syndrome (associated with DiGeorge syndrome)
- 1p36 deletion syndrome
Sample Type:
- Day 5 embryo biopsy
This is an ideal option for expanding testing coverage while maintaining cost-effectiveness.
Advanced Technology - The Foundation of Exceptional Accuracy
All PGT tests at Eurofins GENTIS are performed using Illumina’s Next-Generation Sequencing (NGS) platform, one of the world’s leading genetic sequencing technologies.
Key Advantages:
- Over 99% accuracy for target markers
- Simultaneous analysis of multiple gene regions
- Enhanced sensitivity for detecting small abnormalities
In addition, specialized bioinformatics software enables comprehensive data analysis, minimizing errors and ensuring highly reliable results.
CAP Accreditation - International Quality Certification
Eurofins GENTIS has achieved CAP (College of American Pathologists) accreditation, one of the most rigorous standards in medical laboratory testing. This certification confirms the laboratory’s professional expertise, strict quality control procedures, and the reliability of its test results.
Benefits of PGT in Assisted Reproduction
The application of PGT offers many practical benefits for couples undergoing fertility treatment:
- Detection of Genetic Abnormalities in Embryos:
PGT identifies chromosomal abnormalities (PGT-A) and specific gene mutations (PGT-M), helping reduce the risk of passing inherited diseases to future generations. - Improved IVF Success Rates:
Selecting genetically healthy embryos enhances implantation rates, increases pregnancy success, and lowers miscarriage risk. - Support for Optimal Embryo Selection:
Ensures that only embryos without inherited diseases or genetic abnormalities are transferred to the uterus, improving the chances of having a healthy baby.
With its comprehensive PGT testing portfolio, advanced technology, and internationally recognized quality standards, Eurofins GENTIS is contributing significantly to improving outcomes in assisted reproductive medicine. Beyond providing testing services, the organization accompanies families throughout their journey to finding healthy embryos and creating a brighter future for the next generation.
If you are considering IVF or have concerns about inherited genetic conditions, choosing the right PGT test is an important step toward ensuring a safe and successful pregnancy.
[content_more] => [meta_title] => Eurofins GENTIS provides a comprehensive PGT testing portfolio [meta_description] => Preimplantation Genetic Testing (PGT) is becoming an essential tool for improving IVF success rates and reducing the risk of genetic abnormalities. Eurofins GENTIS offers a comprehensive portfolio of PGT tests, utilizing advanced technologies to support t [meta_keyword] => gentis,Pgt [thumbnail_alt] => [post_id] => 1432 [category_id] => 4 ) [6] => stdClass Object ( [id] => 1429 [id_crawler] => [category_product] => NULL [thumbnail] => huyen.8.2021/pshn1.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2026-04-29 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-04-29 15:31:35 [updated_time] => 2026-05-21 14:36:23 [files] => [salary] => [time] => [created_by] => 1 [is_table_content] => 0 [language_code] => en [slug] => Scientific-seminar-Eurofins-GENTIS-updates-PGT-M-testing-at-Hanoi-obstetrics-and-gynecology-hospital [title] => Scientific seminar: Eurofins GENTIS updates PGT-M testing at Hanoi obstetrics and gynecology hospital [description] => On April 28, 2026, at Hanoi Obstetrics and Gynecology Hospital, Eurofins Genetic Testing Service Joint Stock Company held a scientific seminar and professional exchange with doctors, specialists, and midwives from the hospital’s department of assisted reproduction & andrology. The session focused on updating in-depth knowledge about PGT-M testing - one of the key tests in assisted reproduction, which helps screen embryos for single-gene genetic disorders before embryo transfer. [content] =>
Enhancing professional updates in assisted reproduction
Attending the seminar was Dr. Nguyen Thi My Dung, specialist level II – head of the department of assisted reproduction & andrology, along with numerous doctors, experts, and midwives from Hanoi obstetrics and gynecology hospital.
Representing Eurofins GENTIS, MSc. Nguyen Van Huynh - head of R&D, delivered a presentation titled: “Overview of PGT-M testing at Eurofins GENTIS.” The presentation attracted strong interest and active discussions from attending experts, contributing to improved professional knowledge and practical application in treatment.
PGT-M - a solution for genetic disease screening at the embryo stage
PGT (preimplantation genetic testing) is a genetic analysis performed before embryo transfer, helping select the best embryos genetically, free from chromosomal abnormalities or disease-causing genes.
PGT-M is specifically applied for couples at risk of passing single-gene disorders to their offspring, enabling detection and exclusion of affected embryos.
Common groups of single-gene genetic disorders:
Autosomal recessive disorders:
- Thalassemia (HBA, HBB)
- Spinal muscular atrophy (SMN1)
- Congenital deafness (GJB2)
- Citrin deficiency (SLC25A13)
Autosomal dominant disorders:
- Achondroplasia (FGFR3)
- Marfan syndrome (FBN1)
- Familial hypercholesterolemia (LDLR)
- Polycystic kidney disease (PKD1, PKD2)
X-linked disorders:
- Duchenne muscular dystrophy (DMD)
- Hemophilia A, B (F8, F9)
- G6PD deficiency
- Fabry disease (GLA)
Key highlights of PGT-M testing at Eurofins GENTIS
PGT-M testing at Eurofins GENTIS is developed and optimized according to international standards, offering several outstanding advantages:
- Application of bioinformatics software to select genetic markers suitable for the Vietnamese population, optimizing analysis time and cost
- Procedures compliant with ESHRE 2020 recommendations, ensuring standardization and high reliability
- CAP-accredited laboratory for PGT and NIPT services with strict quality control
- Capability to analyze more than 100 genes/diseases, meeting diverse clinical needs
- Combination of direct mutation detection and linkage analysis methods to enhance accuracy
Optimized turnaround time:
- Thalassemia: approximately 12 days
- Other rare diseases: from 20-60 days
Promoting professional collaboration - enhancing treatment quality
Through this scientific seminar, Eurofins GENTIS reaffirmed its commitment to partnering with healthcare institutions in updating advanced testing technologies, contributing to improved diagnostic and treatment outcomes in assisted reproduction.
The close collaboration between Eurofins GENTIS and Hanoi obstetrics and gynecology hospital not only brings professional value but also expands access to modern genetic solutions for patients, aiming toward the goal of giving birth to healthy babies from the very beginning.
In the context of the rapid development of precision medicine, the role of newborn screening testing has become increasingly important. This is the first step in early detection of inborn errors of metabolism (IEM), enabling timely intervention and improving children’s quality of life. However, alongside advances in testing technology come growing challenges in accurately, consistently, and systematically analyzing and interpreting data.
LC-MS/MS – a powerful tool in screening inborn errors of metabolism
According to Dr. Nguyen Huy Dong, LC-MS/MS (liquid chromatography – tandem mass spectrometry) is currently considered the “gold standard” in newborn screening for metabolic disorders. A key advantage of this method is its ability to simultaneously analyze dozens of biochemical markers from a single sample, expanding disease detection capacity and improving screening efficiency.
Unlike traditional methods that focus on only a few biomarkers, LC-MS/MS enables comprehensive evaluation of metabolite groups such as amino acids and acylcarnitines. This is particularly important because IEM disorders often present complex biochemical patterns involving multiple metabolic pathways in the body.
However, the diversity and complexity of the data also require more advanced analysis and interpretation. Relying on a single indicator may lead to inaccuracies, missed diagnoses, or increased false-positive rates. Therefore, modern approaches require evaluating data in an integrated manner, based on characteristic disease models for each disorder.
Challenges in interpreting IEM test results
Currently, more than 100 inborn errors of metabolism have been identified, each with its own distinct “biochemical signature.” This means laboratory specialists must possess extensive knowledge and practical experience to accurately recognize abnormal patterns.
In practice, result interpretation still largely depends on individual expertise, which may lead to inconsistencies between institutions or even among individuals within the same organization. In addition, factors such as sample quality, gestational age, sampling time, and the child’s nutritional status can affect test results, further increasing the complexity of evaluation.
Therefore, the need for an automated interpretation support tool that can standardize and integrate data is becoming increasingly essential. This is also the reason Eurofins GENTIS implemented training on Clinmind software—a technological solution that supports systematic and scientific analysis and interpretation of newborn screening results.
Clinmind – a solution to improve accuracy and consistency
Clinmind software is designed to support experts in analyzing LC-MS/MS data through a multidimensional approach. Instead of focusing on individual indicators, the system allows simultaneous evaluation of multiple parameters, thereby building analysis models suitable for each disease group.
Within the training program, Eurofins GENTIS staff were guided in detail on approaches in newborn screening, including:
Single analyte analysis
This is the basic method in which the concentration of a primary metabolite is measured and compared with a normal threshold (cut-off). It is simple and easy to apply but has limitations in sensitivity and specificity. In addition, cut-off thresholds may need adjustment depending on factors such as sample quality, gestational age, sampling time, and the child’s nutritional status.
Dual analyte analysis
To overcome the limitations of single analyte analysis, combining two biochemical indicators is used to improve sensitivity and specificity. Evaluating the correlation between two metabolites enhances the ability to distinguish between normal and abnormal cases, thereby improving screening effectiveness.
Multiple analyte analysis
This is the most advanced method, allowing simultaneous measurement of multiple amino acids and acylcarnitines in a single sample. By analyzing overall indicators, this approach significantly reduces false-positive rates and increases result reliability. It also enables the detection of multiple conditions in a single test.
Through the application of Clinmind, data from these three approaches can be integrated and analyzed systematically, leading to more accurate and consistent conclusions.
Enhancing team capacity – a foundation for sustainable development
The training program not only helps Eurofins GENTIS staff master the use of the software but also strengthens their expertise in inborn metabolic disorders and modern approaches in newborn screening.
This is part of the company’s long-term strategy to build a highly capable team that meets the increasingly stringent requirements of genetic testing and genomic medicine. Continuous updates in knowledge and technology help ensure service quality and enhance the company’s reputation within the medical community.
Commitment to innovation and technology application
With a sustainable development orientation, Eurofins GENTIS continuously invests in research, development, and the application of advanced technological solutions. The implementation of Clinmind training demonstrates the company’s commitment to improving testing quality and optimizing result interpretation processes.
In the future, Eurofins GENTIS will continue to expand collaboration with domestic and international partners to deliver more comprehensive solutions in genetic testing. At the same time, the company aims to build a precision medicine ecosystem where genetic data is effectively utilized for diagnosis, treatment, and disease prevention.
The Clinmind training program is not only an internal capacity-building activity but also an important step toward standardizing and modernizing newborn screening processes at Eurofins GENTIS. By combining advanced technology with deep expertise, the company is gradually strengthening its position in the field of genetic testing and genomic medicine in Vietnam.
In the context of increasingly personalized medicine, such efforts will play a vital role in improving community healthcare quality, especially in protecting the health of future generations from the earliest days of life.
[content_more] => [meta_title] => Eurofins GENTIS promotes-training-collaboration-on-Clinmind-software-for-newborn-screening-result-in [meta_description] => On April 24, 2026, Eurofins GENTIS organized an internal training program on Clinmind software for interpreting newborn screening test results, led directly by Dr. Nguyen Huy Dong – R&D specialist of the company. This activity is part of the strategy to e [meta_keyword] => Gentis [thumbnail_alt] => [post_id] => 1428 [category_id] => 4 ) )
Eurofins GENTIS excellently wins two prestigious awards at The Best of Vietnam 2026
Eurofins GENTIS Updates Newborn Screening Packages
Prenatal class on labor and pain relief methods during childbirth
Notice Regarding Fraudulent Impersonation of Eurofins GENTIS Requesting Customers to Transfer Delivery Fees for Newborn Screening Test Results
The PGT Testing Process in IVF
Eurofins GENTIS provides a comprehensive PGT testing portfolio
Scientific seminar: Eurofins GENTIS updates PGT-M testing at Hanoi obstetrics and gynecology hospital
Eurofins GENTIS promotes training collaboration on Clinmind software for newborn screening result interpretation
Please fill in the information below to receive our supports and consultations!
Please fill in the information below to receive our supports and consultations!
